Overview:

DLL3-targeted agents, including bispecific antibodies, ADCs, and CAR T-cell therapies, are reshaping the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC). These advances bring new hope to a population with historically limited options. As these therapies become available, it is vital for clinicians to stay current on their clinical efficacy and the unique associated adverse events, such as cytokine release syndrome (CRS) and neurotoxicity (ICANS).

This program brings together expert faculty to discuss the latest advances and enable the integration of these novel DLL3-targeted agents into ES-SCLC care. Through interactive, case-based discussions with a community oncology colleague, participants will gain practical insights and strategies to navigate emerging efficacy data, anticipate and manage therapy-related toxicities, and address the evolving challenges of patient care in this setting.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Describe the rationale and mechanism of actions for emerging DLL3-targeted agents, including bispecific antibodies, ADCs, and CAR T-cell therapies 
• Evaluate the latest trial data on DLL3-targeting therapies in SCLC
• Implement care plans to monitor and mitigate common adverse effects of DLL3-targeted therapies using evidence-based management approaches
• Apply strategies to effectively coordinate care between the community cancer and academic centers

Target Audience:

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour. 

Acknowledgment of Educational Support

This activity is supported by an educational grant from Amgen, Inc.

Have a question for the PER® team?

Email: info@gotoper.com